CN115932265B - 预测cd19抗体治疗在患者中的治疗益处的方法 - Google Patents

预测cd19抗体治疗在患者中的治疗益处的方法

Info

Publication number
CN115932265B
CN115932265B CN202211271570.5A CN202211271570A CN115932265B CN 115932265 B CN115932265 B CN 115932265B CN 202211271570 A CN202211271570 A CN 202211271570A CN 115932265 B CN115932265 B CN 115932265B
Authority
CN
China
Prior art keywords
cells
peripheral
baseline
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211271570.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115932265A (zh
Inventor
J·恩德尔
M·温德尔里奇
R·博克斯哈默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys AG
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG, Incyte Corp filed Critical Morphosys AG
Publication of CN115932265A publication Critical patent/CN115932265A/zh
Application granted granted Critical
Publication of CN115932265B publication Critical patent/CN115932265B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211271570.5A 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法 Active CN115932265B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
EP16171885.3 2016-05-30
CN201780033793.9A CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Division CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Publications (2)

Publication Number Publication Date
CN115932265A CN115932265A (zh) 2023-04-07
CN115932265B true CN115932265B (zh) 2026-04-14

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211271570.5A Active CN115932265B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780033793.9A Active CN109313194B (zh) 2016-05-30 2017-05-30 预测cd19抗体治疗在患者中的治疗益处的方法

Country Status (26)

Country Link
US (2) US20190195879A1 (https=)
EP (2) EP3916392B1 (https=)
JP (2) JP7066639B2 (https=)
KR (1) KR102416144B1 (https=)
CN (2) CN115932265B (https=)
AU (1) AU2017272608B2 (https=)
CY (1) CY1124768T1 (https=)
DK (2) DK3916392T3 (https=)
EA (1) EA201892542A1 (https=)
ES (2) ES2981046T3 (https=)
FI (1) FI3916392T3 (https=)
HR (2) HRP20240670T1 (https=)
HU (2) HUE067450T2 (https=)
IL (1) IL263103B2 (https=)
LT (2) LT3916392T (https=)
MA (2) MA57021B1 (https=)
MD (2) MD3465214T2 (https=)
MX (2) MX388502B (https=)
PL (2) PL3916392T3 (https=)
PT (2) PT3916392T (https=)
RS (2) RS62155B1 (https=)
SG (2) SG10201911958SA (https=)
SI (2) SI3916392T1 (https=)
SM (2) SMT202400204T1 (https=)
WO (1) WO2017207574A1 (https=)
ZA (2) ZA201808647B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) * 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
EP4051317A1 (en) * 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
TWI865644B (zh) * 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20230014026A1 (en) * 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20220184208A1 (en) * 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
AU2011329161A1 (en) 2010-11-15 2013-06-27 Medimmune, Llc Combination therapy for B cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
WO2015195498A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Also Published As

Publication number Publication date
PL3465214T3 (pl) 2021-12-20
JP2019519770A (ja) 2019-07-11
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
IL263103B1 (en) 2023-06-01
SI3916392T1 (sl) 2024-10-30
EP3916392A1 (en) 2021-12-01
ZA201808647B (en) 2021-05-26
HRP20240670T1 (hr) 2024-09-27
DK3916392T3 (da) 2024-05-21
ZA202100296B (en) 2025-05-28
SMT202100291T1 (it) 2021-07-12
MX2018014702A (es) 2019-10-02
NZ748468A (en) 2025-05-30
MA45124B1 (fr) 2021-05-31
EP3465214B1 (en) 2021-04-28
PT3916392T (pt) 2024-06-04
RS65540B1 (sr) 2024-06-28
MA45124A (fr) 2017-12-07
KR20190013980A (ko) 2019-02-11
DK3465214T3 (da) 2021-05-31
FI3916392T3 (fi) 2024-06-03
PT3465214T (pt) 2021-06-30
ES2981046T3 (es) 2024-10-07
EP3916392B1 (en) 2024-05-01
PL3916392T3 (pl) 2024-09-23
BR112018074603A2 (pt) 2019-03-19
IL263103A (en) 2018-12-31
AU2017272608A1 (en) 2018-12-06
US20220283166A1 (en) 2022-09-08
US20190195879A1 (en) 2019-06-27
CN109313194B (zh) 2022-11-04
MX2021014963A (es) 2022-02-24
CN115932265A (zh) 2023-04-07
HUE054860T2 (hu) 2021-10-28
SG10201911958SA (en) 2020-02-27
MX388502B (es) 2025-03-20
ES2878156T3 (es) 2021-11-18
SG11201810159TA (en) 2018-12-28
MD3916392T2 (ro) 2024-10-31
MA57021B1 (fr) 2024-05-31
CA3025823A1 (en) 2017-12-07
RS62155B1 (sr) 2021-08-31
IL263103B2 (en) 2023-10-01
WO2017207574A1 (en) 2017-12-07
SMT202400204T1 (it) 2024-09-16
CN109313194A (zh) 2019-02-05
CY1124768T1 (el) 2022-11-25
HUE067450T2 (hu) 2024-10-28
MD3465214T2 (ro) 2021-09-30
JP2022119764A (ja) 2022-08-17
AU2017272608B2 (en) 2023-08-10
KR102416144B1 (ko) 2022-07-04
LT3916392T (lt) 2024-08-26
JP7511806B2 (ja) 2024-07-08
EA201892542A1 (ru) 2019-06-28
SI3465214T1 (sl) 2021-12-31
LT3465214T (lt) 2021-10-11
JP7066639B2 (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
CN115932265B (zh) 预测cd19抗体治疗在患者中的治疗益处的方法
JP2023112043A (ja) 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
JP2026004466A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
HK40065007A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40065007B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
EA040320B1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
NZ788788A (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients
BR112018074603B1 (pt) Método para identificar um sujeito tendo leucemia linfocítica crónica, e anticorpo anti-cd19

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250316

Address after: Delaware, USA

Applicant after: INCYTE Corp.

Country or region after: U.S.A.

Address before: Praneger, Germany

Applicant before: MORPHOSYS AG

Country or region before: Germany

GR01 Patent grant